HCA

Business profile & competitive position

HCA Healthcare, Inc. is classified in the Healthcare sector, specifically the Medical - Care Facilities industry. As of December 31, 2025, the company operated 190 hospitals: 179 general acute care hospitals with 50,436 licensed beds, seven behavioral hospitals with 714 licensed beds, and four rehabilitation hospitals. Its outpatient footprint includes 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers, spread across 19 U.S. states and England. The facilities deliver inpatient and outpatient medical/surgical care, emergency and diagnostic services, mental health treatment, and ancillary services through ASCs, urgent/walk-in clinics, physician practices, home health agencies, hospices, and rehabilitation facilities.

Scale is the clearest competitive feature in this data set. HCA generated $75.6 billion in 2025 revenue, with roughly 48.9% coming from managed care and other insurers and 14.9% from Medicare. That payer mix reflects a large, commercially insured patient base, which generally supports pricing power. The 8.8% net margin is consistent with a provider that can spread fixed costs across a massive bed base and negotiate rates from a position of market share. However, the ROE of -112.9% is not a profitability problem in the usual sense; for capital-intensive hospital operators, a negative or sharply distorted ROE can arise from significant leverage, shareholder distributions, or low reported equity rather than from an inability to earn money. When read alongside consistent quarterly EPS beats and a positive net margin, the figure points to balance-sheet structure as the dominant driver, not a lack of competitive moat.

Financial posture

HCA currently carries an $87.7 billion market capitalization and trades at a P/E ratio of 13.5. That multiple sits below the premium valuations often attached to faster-growing healthcare sub-sectors, which fits the mature, asset-heavy profile of an acute-care hospital operator. Net margin of 8.8% is a useful benchmark: it suggests the company converts a meaningful share of revenue into profit after all operating and financing costs, a sign of disciplined operations at the facility level.

The beta is 1.11, meaning the stock has historically moved slightly more than the overall market, even though hospitals are usually viewed as defensive businesses. The most unusual metric is the -112.9% ROE. In highly leveraged industries such as medical care facilities, ROE can become negative or volatile when debt finance substitutes for equity, or when accumulated distributions reduce shareholders' equity below zero. Analysts therefore typically pair ROE with cash-flow and debt metrics rather than treating it as a stand-alone quality score. The P/E of 13.5, positive net margin, and $87.7 billion capitalization together frame HCA as a large, profitable, but financially leveraged healthcare services company.

Strategic priorities & outlook

HCA's most recent SEC 10-K filing outlines four operational priorities. First, the company intends to grow its presence in existing markets rather than relying primarily on entering new geographies. Second, it aims to achieve industry-leading performance across clinical, operational, and patient-satisfaction measures. Third, recruiting and retaining physicians and other healthcare professionals is flagged as central to delivering high-quality services. Fourth, HCA plans to advance its digital and artificial intelligence capabilities, reflecting the broader push in hospital systems to use technology for workflow, clinical decision support, and administrative efficiency.

These priorities line up with the operating footprint described in the filing. With 179 general acute care hospitals and sizable behavioral and rehabilitation assets, HCA's growth strategy is mostly incremental: adding service lines, expanding capacity, and deepening market share where it already has scale. The concentration in Florida and Texas is repeatedly highlighted as a risk factor, but it also explains why "grow in existing markets" is a plausible strategy—those states are among the fastest-growing by population and offer attractive commercial insurance demographics. The AI and digital focus is notable because hospital margins depend heavily on labor productivity, length-of-stay management, and revenue-cycle efficiency, all areas where technology is being deployed across the industry.

Macro & geopolitical exposure

The Medical - Care Facilities industry is exposed first and foremost to reimbursement policy. Hospital operators depend on rates set by Medicare and Medicaid, by managed-care insurers, and by state-level programs. Any change in government reimbursement, coding rules, or site-of-service policies can flow directly to revenue and margin. Regulation also extends to licensure, accreditation, patient safety standards, and medical liability rules, all of which differ by state and can materially affect operating costs.

Labor is another macro factor. Hospitals are heavily staffed with nurses, technicians, and physicians, so wage inflation, union activity, and shortages in key specialties can pressure costs faster than revenue can adjust. The geographic concentration in Florida and Texas amplifies state-specific regulatory, economic, and public-health risks. Interest-rate movements matter because the business is capital intensive and typically carries significant debt; higher rates raise refinancing and capital-project costs. Trade and currency exposure are comparatively minor for a domestic care-delivery business, although imported medical devices, pharmaceuticals, and supplies can be affected by tariffs or supply-chain disruptions. England operations add a modest currency dimension, but they are a small portion of the overall footprint.

Recent developments

Recent headlines illustrate both investor attention and potential legal overhang. On September 5, 2026, defenseworld.net reported that AlphaGrep UK Ltd had acquired a new stake in HCA Healthcare. Institutional buying can signal confidence in cash-flow visibility, though a single filing is not a verdict on valuation.

On September 3 and September 1, 2026, Pomerantz Law Firm issued investor alerts saying it was investigating claims on behalf of HCA investors. Law-firm investigations are not findings of wrongdoing and do not imply a settlement or verdict, but they can create headline risk and modest volatility around disclosure or governance questions. On August 28, 2026, Zacks published an article asking whether operational resiliency can protect HCA's long-term profitability, a question that ties back to the 10-K themes of labor, market concentration, and reimbursement pressure.

At the time of the data snapshot, HCA was priced at $405, with an RSI of 46.4 and a 50-day EMA of $407.99. That places the stock essentially on top of its short-term moving average, neither overbought nor deeply oversold, consistent with a name digesting macro cross-currents while reporting solid operating results.

Earnings behavior & post-earnings drift

HCA has beaten earnings estimates in all eight of the most recently reported quarters, giving it a 100% beat rate over that period. The average earnings surprise across those quarters is 6.4%, a healthy cushion relative to the official consensus. The average five-day price move after earnings is +1.75%, and the drift direction is classified as "up," meaning the stock has tended to drift higher in the trading week following releases.

The last four quarterly reports show the pattern in detail. On July 24, 2026, HCA reported actual EPS of $7.59 against an estimate of $7.56, a 0.4% surprise; the stock rose 1.94% the next session and 5.34% over the following five trading days. On April 24, 2026, actual EPS of $7.15 beat the $7.12 estimate by 0.4%, producing a 3.09% next-day gain and only a 0.15% five-day drift. January 27, 2026, was a stronger operational beat: actual EPS of $8.01 versus $7.46, a 7.4% surprise, yet the stock fell 2.89% the next day and 1.31% over five days, showing that a large beat does not guarantee a rally if expectations or forward commentary disappoint. By contrast, the October 24, 2025 report delivered actual EPS of $6.96 against $5.79, a 20.2% surprise, and the stock jumped 4.66% the next day and 2.83% over the next five sessions.

The next scheduled report is October 23, 2026, before the market open, with a consensus EPS estimate of $6.71. The 100% beat rate and 6.4% average surprise suggest HCA has consistently cleared expectations, but the mixed next-day reactions and the size-dependent drift show that the stock's response can depend on the guidance and the unofficial consensus as much as on the headline number.

For a deeper dive into how sell-side and institutional models are interpreting HCA's leverage, reimbursement exposure, and relative valuation against peers in the Medical - Care Facilities industry, it is worth reviewing the full institutional verdict rather than relying on headline numbers alone.